Curiouser and curiouser.
In the company's last 10K it lists Walter Drakeford as President, Co Chief Executive Officer, CFO and Director.
In the next filing, the 10Q Walter Drakeford is listed as CFO.
I can't find any explanation, 8K that explains this change.
Can someone else?

Furthermore that 10Q states:
"Delinquent Payroll Tax Returns and Payments

The Company is delinquent in filing certain Federal and Georgia payroll tax returns resulting in the non-payment of the related withholdings and employer taxes. The delinquency and non-payments are for the quarterly periods ended December 31, 2009, March 31, 2010, June 30, 2010, and September 30, 2010."

This is very rare to be anything but a very negative sign as to the long term viability of a company.

Furthermore it states that Drakeford and Drakeford were paid $60,000 to help handle this severe difficulty with the Federal and State authorities. Hmmm...

Potse - Coincidence?
Sean Marconi and major shareholder listed in 10K have at least one thing in common:
Address is same Florida city...

IIn one of my last posts I suggested that all one needed to do was to read the last couple Q's and K then connect the dots.
Let me make a comment of two - none of this reflects on your posts furcash.

1) Anybody who suggests Dr. Musick as hiring a pump and dump firm simply does not know Dr. Musick, understand what and how he has accomplished what he has over the past ten years.
2) Does anybody know the firm referred to and has anyone checked out exactly what they do?
3) Has anybody called the firm and pretended to be looking to find help, as the owner of a small company, what exactly are their capabilities and what is it they can do to help?
4) Don't forget - it is often times what isn't said in a release, conversation, etc. that is more important than what is said.
5) IMO there is a great deal more here then initially meets the eye.

Anybody who buys over 1,000,000 shares of this stock up 200-300% based on some email pump reflects the image your picture portrays.

WHO IS GLOBANK, CORP?

http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=139062931

2011 10K - Read only if you have a strong stomach!
Sales decline 16.3%
yet
SG&A increases 20.9%

Current payables owed by the company:
$2,575,827

Revenues for 2011 = $5,933,201

The company owes 43% of the Revenues it earned in 2011!!!

Here are some items from the 10K:


Our restricted cash flow raises substantial doubt about our ability to continue operations unless we obtain financing or generate adequate cash flow.

Although we had revenues of $5,933,206 in 2011 and had receivables of $997,195 as of December 31, 2011, our inability to achieve sufficient increases in our revenues has created a liquidity challenge that raises doubt about our ability to continue as a going concern. The auditor’s opinion which accompanies our financial statements is qualified as to our ability to continue as a going concern. Revenues increased in 2010 to $7,088,493 from $6,400,042 in 2008. In addition, collection of medical receivables can be delayed as they are submitted to insurance companies and government agencies, unless we generate sufficient collections on our receivables, otherwise increase revenues or obtain financing through other means, our operations may be difficult to sustain.

MIT faces downward pricing pressures.

MIT believes that continued pressure to reduce healthcare costs could have a material adverse effect on MIT’s revenue. The current market continues to exert pressure on healthcare companies to reduce health care costs, resulting in reduced margins for home healthcare providers such as MIT. Larger group purchasing organizations and supplier groups exert additional pricing pressure on home healthcare providers. These include managed care organizations, which control an increasing portion of the healthcare economy.

Our restricted cash flow raises substantial doubt about our ability to continue operations unless we obtain financing or generate adequate cash flow.

Although we had revenues of $5,933,206 in 2011 and had receivables of $997,195 as of December 31, 2011, our inability to achieve sufficient increases in our revenues has created a liquidity challenge that raises doubt about our ability to continue as a going concern. The auditor’s opinion which accompanies our financial statements is qualified as to our ability to continue as a going concern. Revenues increased in 2010 to $7,088,493 from $6,400,042 in 2008. In addition, collection of medical receivables can be delayed as they are submitted to insurance companies and government agencies, unless we generate sufficient collections on our receivables, otherwise increase revenues or obtain financing through other means, our operations may be difficult to sustain.

On August 1, 2008, we received a term loan from Globank, Corp. (“Globank”) in the amount of $500,000 and used the proceeds to pay off our obligation to a factor. The term loan from Globank, Corp. matured on July 31, 2010. This loan was replaced by a new loan in 2010 with Globank (the “New Loan”). This New Loan accrues interest at a rate of 14.9% per annum and matures on December 31, 2013. The terms of the New Loan requires monthly payments of accrued interest payments plus principal payments of $1,000 per month. A balloon payment of $1,002,727 is due on the maturity date. The New Lloan is secured by our assets and guaranties of the Company’s chief executive officer and our three subsidiaries.

RIP MIT[color=red][/color]

Thanks for the kind comments. About 9 months ago we met with Dr. Musick and had a very productive meeting. Our bottom line desire was to discuss how to help him achieve his goals. Growing the business, improving shareholder value and helping develop products that medically change lives.
We even brought up things like tax loss carry-forward valuations and ways to take advantage of those.

Shortly after our meeting the 10Q was released that addressed some of our discussions. Over the next couple releases it now appears that this meeting either helped solidify his thinking and/or provided some insight for him. As I have been reading the releases, I have felt more comfortable in commenting in a public format. Rewarding himself, his family, shareholders and the thousands of people who would be impacted by the company's patents and his own brilliance is spelled out in these releases, all one has to do is connect the dots.

Success will come down to execution. Frankly, I want to say the extent of the success, but I know there is always more space between the lip and the cup and success still needs to be achieved.

Finally, let me ask y'all one question.
If you were in charge of a major company and the development of a new product or FDA approval was dependent on a source that was nearly a one man shop, would you take the risk or go with an inferior product? My own personal view is that significant top line growth will in all likelihood only be accomplished via a business combination. All of this, I would argue is spelled out in the recent K's and Q. That said, once again the caution is that the money isn't in the bank until it's in the bank...

Ask yourself one question.

If you were Dr. Musick and you spent years and hundreds of thousands of dollars of your personal funds, maintained as low a number of outstanding shares as possible and had developed patented products that have been proven superior to others-

would you let it all go down the toilet or would you seek a return for all your efforts, your family and shareholders?

I believe I was the one to originally bring the tax loss carry forward "value" up. If memory serves me, the prior Q was the first time management mentioned it. Hmmm, hesitate to go into much more detail, connect the dots.

Yes. I added to my position at $0.06. The pressure on the stock could be a combination of low float and year end tax loss selling. Over the past month or so, I have been contacted by market makers and I am pretty sure there has been forced selling due to liquidity issues of a few six figure stock holders. I am not in this for a trade as can be determined from the size of my position, which is why I believe I get calls on occasions from market makers.

I believe I have been as clear as I can on that this is not an easy stock to trade. If the spread doesn't get you the market makers will.
I have not changed my position regarding the stock and if you look at my old emails, even those dating back several years now, I think you will see the consistency of my position:
1. Patent's, intellectual property, etc. have great value.
2. Dr. Musick is a brilliant scientist.
3. Most brilliant scientist do not make good businessmen. Have you seen the movie "Extraordinary Measures"?
4. I respect him and know he wants to be successful as I have had many conversations with him about this and various options to accomplish the goal of providing people with life changing medical treatment via stem cell, etc. In addition, getting compensated for the years he has spent as well as the personal funds he has used. Not just for him, but for his family.
5. The best solution for everyone, in my opinion, would be a combination with a larger company that ideally would take advantage of the tax losses (requiring a reverse merger), let Dr. Musick concentrate on what he does best, move away from the perceived weakness of a one man firm - one reason why I think it has taken so long to begin to generate sales.
6. The risk is that Dr. Musick does not have the skill sets to pull off the business side.
7. Being Sarbannes compliant, with a tax loss carry forward, there should be some anchor to downside protection.

There is nothing in this post that I haven't expressed to management. I own in the neighborhood of 7 figures of common stock because I think the risk/reward is worth the investment and the time. Worse case the stock ends up being worth nothing. I won't like it, but can live with it. Upside potential is difficult to put a number on it because it could be so substantial.

Obviously, my personal conclusion is and has been that the risk/reward is extremely compelling. That there are more combinations to win with this investment then not. While history shows I have a pretty high batting average, many of which documented in print over the past 40 years, I'm not always right.

I hope this helps you in your own deliberations. Let me know if there are any other questions I can give you my opinion on. The OTCBB is populated with gypsies, tramps and thieves. Dr. Musick is and has demonstrated over the years that he is none of the above. Time will tell if he has the skill set to turn this thing into something significantly bigger than himself...

With all the "potential" and with tests proving the superior aspects of their products, the probabilities are quite meaningful that something will happen. Hopefully, which I believe, our work and patience will be well rewarded.

Large buyer today as well...

Conflict of interest? Whose interest was this transaction for? Shareholders or board members?
This doesn't pass the smell test.

From the 10K:

"Thomas J. Duncan

Mr. Duncan became a member of the Board of Directors of MIT in May 2007, and joined the board of directors of Medical Infusion Group in September 2006. Mr. Duncan is employed with Southeast Vending, LLC, where he has been President since 2001, and he is its sole member. He has been President of Southeast Lumber and Construction, Inc. since 2001, and Secretary and Treasurer of both Custom Locators, Inc. and Auto Locators, Inc., since 2000 and 2004, respectively. Mr. Duncan maintains controlling interests in each entity. Since 2005, Mr. Duncan has been a member of the Board of Directors of CNB BanCorp,Inc., the holding company for Citizens National Bank, a national commercial bank based in Windsor Virginia. Mr. Duncan graduated from the University of Georgia in 1976 with a BBA in Accounting. The Board believes that Mr. Duncan has the experience, qualifications, attributes and skills necessary to serve on the Board because of his experience in finance, his having provided leadership and strategic direction to the Company and his unparalleled knowledge of the Company and its business. . Mr. Duncan is not a member of the Board of any other public company or any investment company, neither has he been a member of the boards of directors of such companies for the past five years except for CNB BanCorp, Inc. ]."

JoRok - insight or bag holders?
How many public companies do you know that have to pay 60% interest rate on a loan? Then find out that the new guy Stratford, who was instrumental in the company going public, have direct connections to the company earning that 60%?

That doesn't mean that crooks can't get the stock price higher. Certainly possible and Stratford from what I understand is politically well connected. Not to be to cynical, but I don't have much confidence in the ethics of politicians.

So, while this stock may go higher, in my opinion you need to ask yourself one question:
Do you feel lucky, well, do you?

They already have revealed themselves:
Self serving crooks with vested interests that run counter to shareholder interest. Consider this quote from the current 10Q:

"Globank Corp., interest at 14.9% payable monthly commencing January 1, 2001(interest at 60% in 2009 and 2010), due in monthly installments of $1,000 from February 1, 2011 to December 1, 2013 and a balloon payment of $1,002,727 on January 1, 2014, secured by Company assets and guaranties of the Company’s chief executive officer and the Company’s three subsidiaries (less unamortized debt discounts of $410,000 and $0, respectively) MIT’s newly elected Co-Chairman and Co-President, Walter H.C. Drakeford (“Drakeford”) whom is also the Company’s new Chief Financial Officer, Secretary and Director has had a professional relationship with a financing entity in which the president of Globank is involved in."

I haven't seen anything public.

Yes. The webinar was "well attended"
according to Hemogenix, who has a long, positive history with them. It was VODG's first and besides building customer awareness, logic would tell me that it could (should?) result in creating not only more demand for VODG's products but also VODG's common stock.

I don't think the timing is coincidence.

How cheap is this stock?
Would suggest it is quite cheap.
As long as nobody cares, it won't matter, but give me a moment and let me know what you think.

1. Cummulative deficit is $6,818,524
Most, if not all could be used as a tax loss carry forward.
2. Shares outstanding = 18,478,995. Cummulative deficit per share would be $0.37 versus current price of $0.10 per share.
3. There are some liabilities, most center around deferred compensation. How to handle this?

From the recent Q:
"Effective May 1, 2008, the Company entered into a new Executive Employment Agreement with its CEO. The Agreement established annual base salaries of $80,000, $85,000, and $90,000 over the three years of the Agreement, which was to expire on April 30, 2011. On April 27, 2011 the Company’s board of directors ratified a modification to the original agreement establishing an annual base salary of $12,000 per year, effective February 1, 2011 and continuing for three years. The Agreement also provides for incentive compensation based on the achievement of minimum annual product sales and an option to purchase one million shares of the Company’s common stock that includes contingent vesting requirements. The employment agreement includes changes in control given exercise of underlying stock options and also includes severance provisions."

This is a very clean company, and as a shell with the TLCF, I would argue that the stock is worth 2 to 3 times its current value to an interested party for no other reason than a cheap way to go public.

BIG changes in compensation add to this as well. Salary is now tied to sales - incentive compensation.

Now as a shareholder you got to like this:
1. proven vastly superior products,
2. $12,000 base salary plus incentive compensation based on sales AND Dr. Musick has an option to purchase one million shares of the common stock. I like the rewards being focused strongly on improving the business of the company which will help all shareholders, if accomplished.
3. Seems to me the facts are pointing to a very interesting potential outcome for shareholders and arguably some "anchor" to the overall value of the stock.

Thoughts to ponder, let me know yours,

Another comment on visiting company.
Out of the many numerous times I have met with Dr. Musick, he was clearly the most up beat I can remember. Interesting as well, my "significant other", who has spent a reasonable amount of time with me and Dr. Musick over the years felt the same way.

As we left for the airport, we discussed the meeting, how encouraged he sounded, looked and acted. I think we know him too well to rule out he was just in a good mood and enjoying life that day, although it is a possibility. We talked about what these vibes we both felt could mean.

Our conclusion, was that not only does he feel very good about the group he now has, but that he sees things really coming together and the 10 years he has put into this, where his real payoff will be in the price of the stock, finally starting and obtainable. He spoke about how well he and Dr. Smith worked together, the new products and shared "webinar" that was well attended from people around the world. The exposure VODG has received because of the HemoGenix connection and the additional markets it appears to be opening up, especially in the Far East.

VODG will likely be event driven. Either substantial increases in revenues, a reverse merger, combination or some sort of exit strategy for himself, his family and his shareholders.

Recent meeting with management left me quite encouraged.

1. We discussed quite a few things and I think the news today is reflective of a growing alliance between Dr. Ian Smith and Dr. Jim Musick. Add to that the recent addition (changes) to the board, products that are significantly better than larger competition. There is ample evidence that VODG has developed a solid foundation that could play out several ways, producing ample returns to shareholders.

2. This foundation will likely open up some significant accounts that in the past were not available to VODG.

3. OTCBB - a world of gypsies, tramps and thieves, VODG is a diamond in the ruff. Hard to see how it wouldn't take Dick Tracy too long to figure several ways to win here. By executing business plan or by acquisition of the company by one of its big dog competitors for the science, patents, etc.

Agree with you. In addition to the internet work yesterday, I spent some time on the phone today checking out Duane C. Knight, Jr.'s background to the best of my ability. Did nothing with Neuromonics, Inc., but did follow through on Denver Biomedical, Trinity Capital and Hein & Associates.

I really like what I was told, with the understanding that it is second hand...

The guy has a background that should work very well with Dr. Musick, the business plan and helping shareholders - of which he and his family are rather significant.

Did some research on Duane C. Knight, Jr, Trinity Capital Services, etc.
Their website:
http://www.trinitycapitalllc.com/
Seems like he has a good balance between understanding science, business and getting things done. Probably most aggressive person Dr. Musick has let into his circle.
Any body know the guy or have thoughts?

Thanks for the information.

1. Sorry to hear of you difficulty with OTCBB stocks. There are fantastic opportunities, but along with that comes high risk as well. Furthermore, if you don't know already, my many years of experience have taught me that when investing in these potential diamonds in the "ruff" one must recognize it is a world of gypsies, tramps and thieves. Simple fact of life. Went back to your first post to see when you stated you bought 5,000 shares and what price as well. Check with IRS or your tax accountant, to see if you think it makes average down, take a loss on your shares and wait to buy back in. I think it is a 30 day (calendar not business) period between taking the loss and re-establishing your position
or just wait it out.

2. IF this stock works out the way some of us think, who have been in it for a great deal longer than you have been, you should end up being pleased with your investment.

3. FYI - I went to the link you posted and if you didn't catch it, the fine print at the bottom sounded to me like VODG paid for the interview.

Yes, from what I have been told by specialists in the industry, it has significant importance and what the release seems to be saying is that the business plan is to use that plus the combination, however that might work out, with another "synergistic" company. If it is the obvious one, it would make a great deal of sense in moving both along quicker and much more dramatically than they could do apart. The size would permit the growth and market penetration that would likely lead to development of their own proprietary drugs.

Personally, if it goes that way I think it would be hugely exciting to have been on the ground floor. BUT - as I have consistently said, I am not always right. That said, VODG based on today's announcement and additional information appears to have significantly enhanced the risk/reward for shareholders.

Now to your question.
Here is how it was explained to me by some of the top people at some very large pharmaceutical companies. Some located in Indiana and Illinois for example. I'm a slow learner, especially in this stuff, so I need to pick a lot of other people's brains.

Let's say a major company has 6 possible drugs to treat a certain disease (cancer for example), disorder, etc., etc.

Through cell immortalization, etc. these 6 possible drugs can be narrowed down to 2 or three versus typical time consuming and costly research. So it saves a great deal of money, a significant amount of time and permits a company to focus and enter stage 1 FDA approval on drugs that have a much higher probability of being successful.

I'm sure that there is more, but that is the limit of what or how it has been explained to me by these folks.

Sorry for the length, but as you also know futrcash, I really do my due diligence so when I'm wrong, it isn't for lack of digging into it.

Let me know what you think, where and/or if you disagree, have other or additional information or insight - and that goes for anyone reading this too! Constructive input helps us all.

Hey futrcash. Let's try to put some numbers to this.
Last year company lost $257,000. Average of last three years loss is $314,000.
First Q of this year, company lost $40,000.
Depends on how they handle the $200,000 fee, regardless, sales would have to be up materially to produce profitability. The exact extent depending on exactly what "operations" means.

We got a pretty good idea who the private company is, last I checked they were located about an hour drive south from Denver.

As we have been discussing here, handwriting has been on the wall. Now it is on the tape.

If what we see is true this could turn into something really sweet, especially if it is a reverse merger and as VODG shareholders we end up with a combination of VODG and the company VODG is currently in early stages of negotiations with regarding said combination. That should be a non-taxable event to current VODG shareholders, but double check with your own accountants to be sure.

Like you, thinking patience may well finally be rewarded and "futrcash" will become present cash. Time will tell.

One more SOX comment.
Used to work with companies to help them go public, become SOX compliant. It has been several years so please correct me if I am wrong.
A violation of SOX has a beginning minimum fine of $1 million. To make the forward looking statement that is in the press release, based upon my knowledge carries that kind of weight.

Consider that Sarbannes has moved to OTCBB stocks. For management to say profitable by year end or sooner...
I can not remember Dr. Musick ever stating this before, let alone now that the company has to face SOX compliance.

This is great news, in my opinion.

Totally agree with your comments and remember it is only a five year agreement. Also found your connection to Hemogenix interesting and insightful.

Let me add something else that could be reading into things too much but give me a listen.

The resignation of R. Huebner was not pre or proceeded by a news release. It was followed by what I would call immediately - on a legal calendar - the news release and then 8k of the FSH deal. In that order. I would link the two filings together and come to the conclusion that they spell something significant.

I can only postulate at what it spells. If I let my brain do what it wants and connect these dots we may have just witnessed something that will have great significance to shareholders.

Let me know as well. Thanks.

Interesting comment.
Don't want to split hairs, but I feel a need to respond.

From the beginning of building my position, my single biggest concern has been whether or not Dr. Musick would prove to be a business man. Never doubted the potential future value of the patents, but my experience has been that few "scientists", especially exceptional ones like Dr. Musick are also good, solid business people.

It appears to me that Dr. Musick has surrounded himself with people who can aid him in accomplishing every shareholders goal:
improving shareholder value.

One has to give him great credit for recognizing his needs and setting about to find methods to accomplish them.

I have also seen Dr. Musick become more realistic, in a business sense, of what he can and can't accomplish. Arriving to the conclusion that he needs help, can't direct it all on his own and most importantly, probing with him "exit" strategies that would benefit himself and shareholders. Over the past year or so, I have seen him grow in his understanding and acceptance of these concepts.

Therefore, I would argue that the risk of execution on his part is substantially, and I mean substantially less than what it has been in the past. Here is my final point to your comment:

I would strongly argue that given where things are today - "execution" will take care of itself. Furthermore, that as shareholders, we have moved from the time period of the risk being Dr. Musick doesn't execute the business side to him just not screwing up. My personal opinion has changed to a sense that it is now his to loose, which could happen. Lots of room between the infamous lip and the cup. Things still need to play out correctly so shareholders can walk to the bank. We are far from home free, but today the risk / reward relationship for shareholders has dramatically improved. Dramatically.

Thanks for the update.
I obviously agree with you. In addition, which you may have well, would have been to speak to some of the company's "business partners". They too, are comfortable and quite optimistic about the growing relationship with the Company.
Someone like myself our you, who has come to know and respect Dr. Musick, and has decent business background would not, in my opinion, be doing the right thing to question, encourage, direct, etc. how he can realize financially for himself, his family and shareholders the years he has put into getting VODG where it is today.
Hard to see how anyone could argue that:
1. The patents and their scientific "uniqueness" do not have value, possibly significant.
2. The extent of the value balanced by the amount of time and resources that will be needed offset by a very strong and capable team at VODG, but obviously limited resources.
3. The value of the Company and the increased value in using it as a means for a company to go public minimizing financing expenses and capitalizing on tax advantages, etc.

To be somewhat redundant, I've been investing for over 40 years and learned a long time ago at the wisdom of having an "exit strategy". So while I encourage the Companies I am involved with to think though these concepts, VODG has a special place for me because of what I have seen and how I have seen Dr. Musick conduct himself over the years.

One last thing, if you order a current shareholder listing from STC in Dallas, and had had an earlier one, all of which are available to the anyone who wants to pay and therefore in the public domain, You would see some changes. I think, due to current economic conditions, that some long term investors have had no option but to reluctantly sell stock. Adding the trading volume and comparing it to changes in shareholder holdings, one would likely come to the conclusion that has accounted for (A) some of the recent volume and (B) a decent chunk, over six figures has been sold in what must have been a private transaction.

The pot seems to be simmering here from several different viewpoints. Let's hope our instincts are correct and that Dr. Musick and shareholders will benefit from the years of his work and service to VODG's shareholders.

Yes I have met with and speak with Dr. M on a regular basis. I am very comfortable with what is going on with the fundamentals of the business and concepts on how to unlock shareholder value. I am reluctant to go into more detail because my knowledge base now is rather large and now admittedly blurred as to what is appropriate for me to comment on. However, there have been some other posts that have connected the dots pretty well in my opinion.

If you would spend the time and money to get the listing of shareholders, and do so on a regular basis, you would have additional information on the distribution/accumulation of stock. That too, tells an interesting story.

VODG has taken longer to develop than I thought (usually does for me in these situations). It could end up not turning into the picture I think it will. It won't be for lack of due diligence on my part. But I have enough experience (40+ years on both the buy and sell side) to recognize that all the due diligence in the world doesn't guarantee success.

Outstanding K and great job in connecting the dots with the Q's.
Besides the great presentation of the information you all have done there is one other very significant motivating factor that should favor shareholders.

Follow the money.

From the balance sheet:
Accrued to Dr. Musick: $1,350,053
Plus the number of shares he owns.
I will bet with a man who has not screwed shareholders by flooding the market place with certs, poured his life into the science and development, supplements working capital with his own funds... if anyone has a brain when you take the information presented plus the money and you don't bet with this guy...

Plus two solid options to success - internally.

Or "external", one that would compensate shareholders and the good doctor plus take advantage of the TLCF giving all a great payback plus the potential play in a synergistic combination. That is my own personal choice as I believe it would maximize return and options to all currently involved.

The sparks seem obvious, a fire is but a matter of time, one that will warm the hearts of shareholders.

The report from TradeLibrary and the positive spirits, etc. that he communicated from his visit, I would re-iterate based upon my own recent contact. Furthermore, if I were a betting person, logic or just connecting the dots leads me to think the positive, upbeat feelings that a couple of us have had with Dr. Musick will likely be reflected in the 10K. And if my memory is correct it is typically released somewhere around this time of year. Let's hope we are correct and it makes for interesting reading.

Within the next two weeks, end of January at the latest. Have several important meetings to schedule in a couple different cities. Will keep you informed and pleased to include your question when we meet.

Will be flying into Denver for business and hope to arrange a meeting with management at VODG. Anybody want to submit a question(s) in case we can get together?
I have two that I hope I can get some sense of...
1. How's the top line doing.
2. Does or is Dr. Musick thinking about a reasonable exit strategy.

Not sure if our schedules will mesh, but will do my best to arrange a meeting.

Me too, hopefully we will love the words and be excited about them...

Just spoke with the company, wanted to offer congratulations on the press release.

Dr. Musick's voice (have known him and followed what he's been doing for long time) reflected what I know has to be great pleasure in the information that was just released. He has worked very hard, minimized stock issuance for shareholders sake. Have to give him a great deal of credit for what he has done.

So, is Rip Van Winkle starting to wake up?

Now, this is my personal interpretation not just what was said, nothing was said outside of the press releases, but - hear this - the "energy" behind how he spoke was quite obvious and very enthusiastic for him, very.

Based on the press releases, hookup with Hemo and some other important "business" people on the board, I think we are finally getting pretty close to the company starting to start doing well. Think about it, if the press release is correct, how can this not work???

Time will tell, but, as you know, my money's down and it sure seems like Rip Van Winkle is finally starting to wake up.

Understand your comment. I know Dr. Musick, very well on a business basis. Timing here is what it is, that said, not to go to philosophical on you but there is a translation of the bible, The Message, that states "timing is the Father's business". I'm comfortable with the completeness of my work and responsibility, and for me recognize where the real control of time comes from.